Vince & Associates Clinical Research, a premier provider of early phase
clinical research services to the global biopharmaceutical industry,
announced the release of the print publication of scientific data for
Dyax Corp.’s (Dyax) DX-2930 monoclonal antibody in a first-in-human
study in the Annals of Allergy, Asthma & Immunology.
The paper describes the results from the first-in-human clinical study
of DX-2930 which met all of its objectives of assessing safety,
tolerability and pharmacokinetics of this investigational drug
candidate. Additionally, the data indicates that DX-2930 has a half-life
of 17-21 days in humans. DX-2930 is being developed for the prophylactic
treatment of hereditary angioedema (HAE) attacks and is currently being
evaluated in a Phase 1b study in patients with HAE. The complete
publication can be accessed online www.annallergy.org/article/S1081-1206(14)00377-9/pdf.
“Our clinical research partners play an integral role in the DX-2930
development program,” said Ryan Iarrobino, Senior Director, Clinical
Development at Dyax. “Vince & Associates has expertise in early-stage
human trials, state-of-the-art facilities, and excellent capabilities
with subject recruitment and retention, all important qualities that we
look for in our collaborators.”
Dr. Brad Vince, CEO and Medical Director at Vince & Associates,
commented: “It is essential for Vince & Associates to work with
companies that are at the forefront of drug discovery such as Dyax as it
enables our organization to support important research and development
initiatives for promising new therapies.”
Vince & Associates offers clinical pharmacology expertise to support
monoclonal antibody development plans especially when entering into
Phase I clinical trials. Clinical trials for biologics require
experience and specialty knowledge. Immunogenicity, rare adverse events,
and efficacy are all factors to take into consideration when developing
a biologic.
About Vince & Associates Clinical Research
Vince & Associates Clinical Research has provided clinical research
services to the biopharmaceutical industry for 15 years. The research
professionals at Vince & Associates are proud to be recognized in the
industry as a “Center of Research Excellence.”
Vince & Associates currently operates a state-of-the-art,
multimillion-dollar, 100-bed clinical pharmacology unit that combines
the ultimate in subject safety and luxury. This early development unit
has the upscale atmosphere necessary for the recruitment and retention
of study volunteers in both short and long-term clinical trials. From
the safety and security of the controlled access unit to the added
features of a movie theater and game rooms, no detail has been
overlooked.
About Altasciences
Altasciences is the parent company of wholly owned subsidiaries Vince &
Associates Clinical Research (Kansas, USA) and Algorithme Pharma
(Quebec, Canada). Both organizations provide comprehensive early stage
clinical services in Phase I/IIa, including the necessary support
services in this critical stage of drug development.
More Information
Additional background materials pertaining to Vince & Associates
Clinical Research are located on the corporate website at www.vinceandassociates.com.
About Dyax
Dyax is a fully integrated biopharmaceutical company focused on the
development and commercialization of novel biotherapeutics for unmet
medical needs. The Company currently markets KALBITOR®
(ecallantide) for the treatment of acute attacks of HAE and is
developing DX-2930, a fully human monoclonal antibody, for the potential
prophylactic treatment of HAE. Additionally, Dyax has broadly licensed
its phage display technology and has a portfolio of product candidates
being developed by multiple licensees that it refers to as the Licensing
and Funded Research Portfolio.
For additional information about Dyax, please visit www.dyax.com.
For additional information about KALBITOR, including full prescribing
information, please visit www.KALBITOR.com.
Copyright Business Wire 2014